Hope for Meniere's sufferers: new drug enters final testing phase

NCT ID NCT06859788

Ongoing Disease control Sponsor: Sound Pharmaceuticals, Incorporated Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This study tests a drug called SPI-1005 in 200 adults with Meniere's disease, a condition that causes hearing loss, ringing in the ears, and dizziness. Participants will take the drug twice a day for 6 or 12 months to see if it is safe and tolerable. The goal is to find a treatment that can help control the disease over the long term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENIERE'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dizziness hearing loss disorder Meniere disease Tinnitus Vertigo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MENIERE'S DISEASE MÉNIÈRE'S DISEASE

Contacts and locations

Locations

ENT and Allergy Associates of Florida

Boynton Beach, Florida, 33471, United States
ENT and Allergy Associates of Florida

Delray Beach, Florida, 33484, United States
ENT and Allergy Associates, LLP

New York, New York, 10017, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Medical University of South Carolina

Charleston, South Carolina, 29425, United States
Northwell Health

New Hyde Park, New York, 11042, United States
The House Institute

Los Angeles, California, 90057, United States
Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States
University of Texas Southwestern

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.